Trial Profile
A Study Evaluating The Efficacy of Long-Term Bosentan Treatment In Reducing The Risk of Developing Pulmonary Arterial Hypertension (PAH) In Patients With Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Oct 2016
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary arterial hypertension; Ulcer
- Focus Therapeutic Use
- 28 Oct 2016 New trial record